The episode explores how the PARITY trial transformed orthopedic oncology by establishing that extended postoperative antibiotics do not reduce infection after endoprosthetic reconstruction, while increasing drug-related complications. The discussion highlights the global collaboration needed to enroll 600 rare oncologic cases across 12 countries, the structured process for generating 13 secondary analyses from this rich dataset, and the growing culture of teamwork and methodological rigor shaping future trials. It closes with a look ahead to major upcoming studies in sarcoma surveillance and metastatic bone disease and the drive to mentor the next generation in large-scale clinical research.